ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Late-Breaking Study Results of the Supreme HT™ Healing-Targeted DES Demonstrated Equivalent Outcomes with Exceptional Safety
November 18, 2020SINOMED® announced that Prof. Alexandra Lansky from the Yale School of Medicine, USA, presented data from its first inter-continental PIONEER III study comparing the safety and efficacy of the Supreme HT (Healing-Targeted) Drug-Eluting Stent ... -
SINOMED® Completes One-Year Follow-Up of the PIONEER-III European, US and Japanese Trial of the BuMA Supreme® Coronary Drug-Eluting Stent
July 13, 2020SINOMED, a developer of innovative neuro- and cardiovascular technologies, announced the completion of the 1-year follow-up in the PIONEER-III, randomized global trial evaluating the BuMA Supreme Drug-Eluting Coronary Stent (DES).
Pharma Sources Insight January 2025
